Historique
Article de Périodique
Seizure-induced by phosphodiesterase-5 inhibitors for recreational use: an emerging problem among young people! [Letter to the Editor] (2015)
Auteur(s) :
R. S. CALABRO ;
R. DE LUCA ;
T. BALLETTA ;
M. RUSSO ;
A. NARO ;
P. BRAMANTI
Article en page(s) :
137-138
Domaine :
Autres substances / Other substances
Langue(s) :
Anglais
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus géographique
ITALIE
Thésaurus mots-clés
PHENOMENE EMERGENT
;
SILDENAFIL
;
USAGE RECREATIF
;
EFFET SECONDAIRE
Résumé :
The introduction of sildenafil in 1998 can be considered the watershed in the pharmacological treatment of erectile dysfunction (ED), because of its broad efficacy for different types of ED. Since then, vardenafil, tadalafil and, more recently, avanafil have joined sildenafil to compete in the ED market. These drugs are usually well tolerated, although phosphodiesterase 5 inhibitors (PDE5i) adverse events may include headache, flushing, nasal congestion, dyspepsia, visual disturbance, and myalgia/back pain. Moreover, even generalized epileptic seizures have been reported in patients taking sildenafil (Calabrò, Polimeni, & Bramanti, 2011; Gilad, Lampl, Eshel, & Sadeh, 2002). Nevertheless, due to their safety and tolerability, PDE-i are commonly used in nearly all kind of ED, including neurogenic one (Calabrò, Polimeni, & Bramanti, 2011). According to a recent study, 21.5% of healthy men, aged 18–30 years, used PDE5i as a recreational drug, mostly associated with alcohol or other drugs without medical control, leading to misuse and a public health problem (Bechera, Casabé, De Bonis, Helien, Bertolino, 2010). [Extract]
Affiliation :
IRCCS "Centro Neurolesi Bonino-Pulejo", Messina, Italy